A. Fay, R. Moreira, P. N. Nunes Filho, C. Albuquerque, C. Barrios
{"title":"The management of immune-related adverse events associated with immune checkpoint blockade","authors":"A. Fay, R. Moreira, P. N. Nunes Filho, C. Albuquerque, C. Barrios","doi":"10.1080/23809000.2016.1142827","DOIUrl":null,"url":null,"abstract":"ABSTRACT Immunotherapy has become an important component of modern oncology therapy. Recently methods of immune checkpoint blockade include; anti-CTLA-4, anti-PD-1/PD-L1, or a combination of both therapies and have been developed with the objective of restoring immune system T-cell responses against cancer. This strategy has demonstrated important clinical activity in different tumor types and is currently approved for the treatment of several malignancies worldwide. However, the experience gathered so far with this strategy has revealed emerging immune-related adverse events (irAEs) that deserve particular attention. irAEs can affect any organ or system and require adequate diagnosis, rapid recognition and appropriate management as they may have an impact on the outcome of patients receiving these therapies.","PeriodicalId":91681,"journal":{"name":"Expert review of quality of life in cancer care","volume":"1 1","pages":"89 - 97"},"PeriodicalIF":0.0000,"publicationDate":"2016-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23809000.2016.1142827","citationCount":"12","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert review of quality of life in cancer care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/23809000.2016.1142827","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 12
Abstract
ABSTRACT Immunotherapy has become an important component of modern oncology therapy. Recently methods of immune checkpoint blockade include; anti-CTLA-4, anti-PD-1/PD-L1, or a combination of both therapies and have been developed with the objective of restoring immune system T-cell responses against cancer. This strategy has demonstrated important clinical activity in different tumor types and is currently approved for the treatment of several malignancies worldwide. However, the experience gathered so far with this strategy has revealed emerging immune-related adverse events (irAEs) that deserve particular attention. irAEs can affect any organ or system and require adequate diagnosis, rapid recognition and appropriate management as they may have an impact on the outcome of patients receiving these therapies.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
